Mercy Offers New Hereditary Cancer Testing for High-Risk Patients
A screening tool aims to identify patients at high risk for cancer who may benefit from germline or hereditary DNA testing.
Read MorePosted by CLP Edit Staff | Nov 13, 2025 | Cancer |
A screening tool aims to identify patients at high risk for cancer who may benefit from germline or hereditary DNA testing.
Read MorePosted by CLP Edit Staff | Nov 7, 2025 | Prostate |
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
Read MorePosted by Alyx Arnett | Oct 30, 2025 | Cervical (HPV) |
Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care.
Read MorePosted by CLP Edit Staff | Oct 24, 2025 | Cancer |
PATHFINDER 2 study results indicate more than half of cancers detected by Galleri test were found in early stages, with three-quarters having no current screening options.
Read MorePosted by CLP Edit Staff | Oct 24, 2025 | Prostate |
A study of over 10 million men reveals frequent testing of patients unlikely to benefit, raising questions about current screening practices.
Read More